BeiGene Korea expands market dominance by conducting clinical trials to achieve competitiveness in the Korean market.

Based on this year's Ministry of Food and Drug Safety (MFDS)'s clinical trial approval report, two out of ten approved clinical trial applications were BeiGene Korea's Phase 1 clinical trials.

BeiGene has been strengthening its pipeline of solid cancers, focusing on the PD-1 inhibitor, 'Tevimbra (tislelizumab).'

The company was approved to conduct Phase 1 clinical trials for its new drug candidates, 'BGB-58067' and 'BG-C137.'

BGB-58067 is a new drug candidate designed to avoid the hematological toxicity typically associated with PRMT5 inhibito